Live
Clinical OMICsReduced Glaucoma Risk Connected to Migraine Medication UseScienceIn the remote Amazon, locals are saving a giant fish—and helping their villagesClinical OMICsBroader Immune Targeting Increases Immunotherapy Benefit in Colorectal CancerClinical OMICsAutism Screening Proposed for Children with EpilepsyClinical OMICsImmune Mapping Links Sex-Specific Genetics to Autoimmune DiseaseFierceBiotechBanyan BioInnovations puts down roots with $100M, Icon partnershipEndpoints NewsAmazon adds Ozempic pill to same-day prescription drug kiosks10x Genomics News10X Genomics faces earnings test as AI promise meets funding reality - Investing.com Nigeria10x Genomics Blog10X Genomics faces earnings test as AI promise meets funding reality - Investing.comScienceMagic mushroom compound shows promise against cocaine addictionBioWorldRegulatory actions for May 7, 2026BioWorldUS FDA tries out 1-day inspections
Endpoints News Mar 23, 2026

Apogee shares positive mid-stage maintenance data for eczema drug that could challenge Dupixent, Ebglyss

Apogee shares positive mid-stage maintenance data for eczema drug that could challenge Dupixent, Ebglyss

Original
Body unavailable. Use the original source.